Peptides are increasingly entering drug development pathways as potential active pharmaceutical ingredients due to their large chemical space, relative ease of synthesis, ready availability of low cost starting materials and general low toxicity. As a result, approximately 60 peptide-based drugs have been approved by the FDA, 140 peptidic drugs are currently under evaluation in clinical trials and a further 500 peptides are in development. Success stories include the prostate cancer drug Lupron™ from Abbott Laboratories, with global sales of more than US$2.3 billion in 2011. Understandably, research into the area of new peptide drugs is at an all-time high.
With synthesis visualization software, higher loading capacity in purification, and effective evaporation technology, Biotage has developed a suite of technology to support the whole peptide workflow.
Download the white paper below (PPS468)
New Findings presented at ASMS 2018
Webinar: A Roadmap to Successful Flash Chromatography
Evaporate Water from Reaction Mixtures in Less Than 10 Minutes
Evaporation of Heat-sensitive Compounds
Quick and Easy Removal of High Boiling Solvents